Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01

Ontario Industry Updates
Written By Doriane Rey

Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), recently announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01.

Doriane Rey
Previous

New Partnership Between Aridhia and Replica Analytics Powers Rapid, Secure and Compliant Use of Health Data
Next

OBIO's Business Development Skills Program Featured in Canadian Healthcare Technology